On August 29, 2019, Heska Corporation (“Heska” or the “Company”), a provider of advanced veterinary diagnostic and specialty healthcare products, announced the realignment of its executive officers in support of its strategic growth objectives.

In that regard, Mr. Jason A. Napolitano will cease serving as the Company’s Chief Operating Officer effective immediately in order to enable him to focus his time in his other role and under his new title – Chief Strategy Officer. The Company believes this change will afford Mr. Napolitano the opportunity to increase his attention on business development efforts as the Company seeks to expand its product offerings and access to the global companion animal health market.

In connection with the realignment, the Company also announced the promotion of Nancy Wisnewski, Ph.D, from Executive Vice President, Diagnostic Operations and Product Development to Executive Vice President, Chief Operating Officer, reporting effective immediately to Heska’s Chief Executive Officer, with continuing responsibility and oversight for the Company’s operations, engineering and manufacturing, research and development, supply chain, customer experience, quality control, and advisory to the Company’s Chief Executive Officer. In her expanded role, Dr. Wisnewski will also be responsible for the alignment and prioritization of Company resources to ensure operational excellence and scalability across the Company. Additional information concerning Dr. Wisnewski, her business experience, and the positions and offices historically held by her within the Company are included in Part I to the Company’s annual report on Form 10-K for the year ended December 31, 2018, filed by the Company with the Securities and Exchange Commission (the “Commission”) on March 7, 2019 (the “Annual Report”), under the caption “Executive Officers of the Registrant”, which information is incorporated herein by reference.

There are no arrangements or understandings between Dr. Wisnewski and any other person in connection with her appointment to her new position at the Company, and she does not have any family relationships with any director or executive officer of the Company or any person nominated or chosen to become a director or executive officer of the Company. There also are no “related person” transactions (within the meaning of Regulation S-K, Item 404(a) of the Commission) between Dr. Wisnewski and the Company, and she did not enter into any new plans, contracts or arrangements with the Company in connection with her promotion.

Forward-Looking Statements

This current report on Form 8-K contains forward-looking statements regarding Heska’s future financial and operating results and expectations about the future performance of its management. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that there is an inherent risk in using past results to predict future outcomes, including financial results and perceived or expected behavior. Factors that could affect the business and financial results of Heska generally include, but are not limited to: risks related to the anticipated performance of senior management and Heska’s ability to attract and retain key personnel; risks related to reliance on third parties to develop and manufacture products for Heska; risks related to the commercialization of new products; uncertainties related to attempts to expand into international markets, including uncertainties

related to timing, profitability and currency effects; uncertainties related to Heska’s ability to measure and predict trends in the veterinary market; uncertainties related to Heska’s ability to measure and predict the effectiveness of commercial relationships; uncertainties related to the future impact of recent and other business development activity; risks related to Heska’s reliance on third-party suppliers, which is substantial; competition; and other risks set forth in Heska’s filings and future filings with the Commission, including those set forth in the Annual Report.

About HESKA CORPORATION (NASDAQ:HSKA)

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It offers blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.